Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Penumbra (PEN)
NYSE:PEN
Holding PEN?
Track your performance easily
PEN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$148.00 - $277.34
Previous Close$204.71
Volume244.60K
Average Volume (3M)445.60K
Market Cap
$7.95B
Enterprise Value$7.84B
Total Cash (Recent Filing)$339.69M
Total Debt (Recent Filing)$228.82M
Price to Earnings (P/E)597.9
Beta1.16
Next Earnings
Oct 30, 2024EPS Estimate
$0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.34
Shares Outstanding38,843,936
10 Day Avg. Volume300,163
30 Day Avg. Volume445,603
Standard Deviation0.14
R-Squared0.04
Alpha0.00877
Financial Highlights & Ratios
Price to Book (P/B)6.85
Price to Sales (P/S)7.01
Price to Cash Flow (P/CF)87.90
P/FCF Ratio107.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.92
Enterprise Value/Gross Profit11.49
Enterprise Value/Ebitda-165.55
Forecast
1Y Price Target
$208.86Price Target Upside2.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
Penumbra News
Bulls Say, Bears Say
Bulls Say
FDA ApprovalThunderbolt could receive FDA clearance.
Innovation And GrowthPEN should benefit from expanding Mechanical Thrombectomy penetration, driven by innovation and upcoming data read-outs highlighted by physicians as key drivers of end-market growth acceleration.
Market ExpansionInterest in Thunderbolt appears high with a majority believing it will be market expansive upon its anticipated release in 2025.
Bears Say
Competitive LandscapeThere is lingering concern over the durability of growth for PEN in this segment, particularly alongside an increasingly competitive commercial landscape.
Earnings GuidanceManagement lowered its 2024 revenue guidance substantially.
Product Launch DelaysMacro headwinds in China, product launch delays in Europe, and an unfinalized winddown of the Immersive Health business will also decrease FY24 revenue.
---
Ownership Overview
3.45% Insiders
43.67% Mutual Funds
― Other Institutional Investors
31.76% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PEN FAQ
What was Penumbra’s price range in the past 12 months?
Penumbra lowest stock price was $148.00 and its highest was $277.34 in the past 12 months.
What is Penumbra’s market cap?
Currently, no data Available
When is Penumbra’s upcoming earnings report date?
Penumbra’s upcoming earnings report date is Oct 30, 2024 which is tomorrow.
How were Penumbra’s earnings last quarter?
Penumbra released its earnings results on Jul 30, 2024. The company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.556 by $0.084.
Is Penumbra overvalued?
According to Wall Street analysts Penumbra’s price is currently Undervalued.
Does Penumbra pay dividends?
Penumbra does not currently pay dividends.
What is Penumbra’s EPS estimate?
Penumbra’s EPS estimate is $0.69.
How many shares outstanding does Penumbra have?
Penumbra has 38,843,937 shares outstanding.
What happened to Penumbra’s price movement after its last earnings report?
Penumbra reported an EPS of $0.64 in its last earnings report, beating expectations of $0.556. Following the earnings report the stock price went down -3.466%.
Which hedge fund is a major shareholder of Penumbra?
Among the largest hedge funds holding Penumbra’s share is PRIMECAP Management Co. It holds Penumbra’s shares valued at 7M.
---
Penumbra Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$208.86 (2.03% Upside)
$208.86 (2.03% Upside)
Blogger Sentiment
Bullish
PEN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 6.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.04%
12-Months-Change
Fundamentals
Return on Equity
1.28%
Trailing 12-Months
Asset Growth
7.12%
Trailing 12-Months
Company Description
Penumbra
Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers thrombectomy, embolization, access, neurosurgical tools, ruby coil system, lantern, penumbra occlusion device (POD) system, packing coil, and indigo systems products. Its target markets include interventional neuroradiologists, neurosurgeons, and interventional neurologists; and interventional radiologists, vascular surgeons, and interventional cardiologists. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA.
---
PEN Earnings Call
Q2 2024
0:00 / 0:00
---
PEN Stock 12 Month Forecast
Average Price Target
$208.86
▲(2.03% Upside)
Technical Analysis
Best Analysts Covering PEN
1 Year
1 Year Success Rate
10/14 ratings generated profit
1 Year Average Return
+11.46%
assigned a buy rating 3 months ago
Copying David Rescott's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +11.46% per trade.
---